

## Change of Chair

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) advises that Dr. Lindley Edwards has resigned as Non-Executive Chair of the Company, effective 18 May 2026, for personal reasons. The Board acknowledges and thanks Dr. Edwards for her contribution during her tenure and wishes her well.

### Appointment of Non-Executive Chairman - David Tasker

The Board is pleased to announce the appointment of Mr David Tasker as Non-Executive Chairman, effective immediately.

Mr Tasker is the Managing Director and co-founder of Chapter One Advisors, a Perth-based, strategy and outcomes-focused boutique investor relations and media relations agency. He brings more than two decades of experience across investor relations, corporate communications, and capital markets advisory - including more than 13 years as National Director, Investor Relations at PPR, at the time one of Australia’s largest integrated public relations companies.

He holds a Bachelor of Commerce (Marketing and Management) from Murdoch University.

Mr Tasker has provided investor relations and communications consulting services to Memphasys for more than 7 years and is a longstanding and significant shareholder of the Company. This combination of deep operational knowledge, strong stakeholder relationships, and direct shareholder alignment positions him well to support the Company’s continued commercial progress as a Non-Executive Chairman.

On his appointment, Mr Tasker commented:

*“I am honoured to take on the Chairman role at what is a genuinely exciting time for Memphasys. Felix™ has moved beyond clinical validation into active commercial execution - with growing order flow from key MENA partners, CE Mark approval now unlocking Europe and multiple CE-recognised markets, and a lean, focused team delivering real results on the ground. I look forward to continuing to support Hassan and Marjan at an operational level as the Company accelerates the execution and delivery of commercial agreements, and to working alongside all shareholders in the pursuit of sustainable returns from this outstanding technology.”*

### Recent Commercial Progress

Mr Tasker’s appointment comes as Memphasys continues to build meaningful commercial momentum across multiple key markets. Recent milestones include:

- Record March 2026 quarter revenue exceeding A\$100,000, representing the Company’s transition to a revenue-generating business, with repeat cartridge orders across Europe, MENA and Japan underpinning a recurring revenue model.<sup>1</sup>

<sup>1</sup> Refer ASX announcement dated 17 April 2026

- Institutional adoption of Felix™ at Hamad Medical Corporation (HMC), Qatar's largest IVF institution, with initial ordering of approximately 100 cartridges per month supporting ~1,500 IVF cycles annually<sup>2</sup>;
- CE Mark approval secured (December 2025) enabling immediate clinical use of Felix™ across Europe and CE-recognised MENA markets including Qatar<sup>3</sup>;
- Exclusive MENA distribution agreement with International Technical Legacy (ITL) upgraded to A\$390,000 with territory expanded to include Turkey as the first EU-member state<sup>4</sup>; and
- A long-term European supply agreement secured and operating costs reduced by 40%, supporting a leaner and more commercially focused operating model.<sup>5</sup>

**Authorised by the Board of Memphasys Limited.**

ENDS

For further information, please contact:

Colin Jacoby  
Chapter One Advisors  
E: [cjacoby@chapteroneadvisors.com.au](mailto:cjacoby@chapteroneadvisors.com.au)

### **About Memphasys**

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: [www.memphasys.com](http://www.memphasys.com)

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

### **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys's current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions.

Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an

<sup>2</sup> Refer ASX announcement dated 2 February 2026

<sup>3</sup> Refer ASX announcement dated 29 December 2025

<sup>4</sup> Refer ASX announcement dated 18 September 2025

<sup>5</sup> Refer ASX announcements dated 23 December 2025

at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Memphasys, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Memphasys cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Memphasys will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For personal use only